Kornimate/medical-research-clean huggingface dataset:
effects of ultrasound-guide hypertonic dextrose injection for chronic subacromial bursitis

Conditions: Chronic Shoulder Pain

Summary: the aim of this study is to investigate the echoguide hypertonic injection and compared steroid injection in subacromial bursitis patients about clinical and ultrasound image presentation.

subacromial bursitis is one of the major causes of chronic refractory shoulder pain. it can cause patients with shoulder pain when shoulder exercise and heavy lifting and limiting the range of motion. it can also influence the sleep quality due to pain symptoms of the shoulder. usually, these patients had limited response to medication and physical modality. steroid injection was often adopted for intervention, but the adverse effects should be considered. therefore, prolotherapy was taken as an alternative treatment for chronic subacromial bursitis. it involves the injection of small volumes of an irritant agent, most commonly a hyperosmolar dextrose solution, at the lesion site. hyperosmolar dextrose appears to be the most commonly used agent today. the aim of this study is to investigate hypertonic injections in subacromial bursitis patients about clinical and ultrasound image presentation. the investigators conducted a double-blinded randomized controlled trial for 60 participants with chronic shoulder pain for 3 months with subacromial bursitis. in the study group, the echo guide 20% dextrose water was injected into the lesion site, and the control group received the echo guide steroid injection. rom, spadi, vas, x-ray, and ultrasound data were obtained at baseline. at weeks 2, 6, 12, rom, spadi, vas, and ultrasound data were evaluated. the anova and independent t-test are applied for analysis by spss 20.0 with a p value less than 0.05 as statistical significance.

Eligibility criteria:
inclusion criteria: * aged more than 20 years old with diagnosis of chronic supraspinatus tendinosis by ultrasound and clinical shoulder pain lasting for more than 3 months. exclusion criteria: * history of shoulder fracture and operation, with frozen shoulder or full thickness ruptur of rotator cuff, steroid, or hyaluronic acid, or platelet rich plasma (prp) injection during the period of intervention and following up.

Keywords: prolotherapy subacromial bursitis ultrasound
an approach to "move a little & often" with health conditions

Conditions: Depression; Multiple Chronic Conditions

Summary: people with long term conditions such as diabetes and arthritis, and who also have depression spend a lot of time sedentary during the day. this is because they face many barriers to being active, such as pain and fatigue. being sedentary is problematic because it is associated with poorer health in the long term. common sedentary behaviours are watching television and using the computer; these behaviours are labelled as screen-based sedentary behaviours. an intervention to reduce these behaviours could improve mental and physical wellbeing. the aim of the study is to explore the acceptability of an intervention to "move a little and often" in people with depression symptoms and long term conditions. the investigators will explore the intervention's acceptability using interviews and will examine if the intervention is associated with a reduction in time spent sedentary. results will help refine the intervention further. the feasibility study is part of a phd project funded by the national institute of health research (nihr) collaborations for leadership in applied health research and care (clahrc) greater manchester

there is a growing focus in research on the need to reduce sedentary behaviours. studies have shown that independently of moderate to vigorous physical activity, the amount of time spent sedentary predicts poorer health outcomes. this means that in addition to exercising, it is important to reduce prolonged periods of sedentary behaviours to improve health. for people with depression and long term conditions, milder forms of physical activity may be more appropriate due to higher levels of pain and fatigue resulting from exercise. reducing sedentary behaviours by substituting them with mild physical activities such as walking is a potential avenue to improve health outcomes in this population group. to date, no intervention has been developed to reduce prolonged periods of sedentariness in people with depression and long term health conditions within the uk. this feasibility study aims to refine a behaviour change intervention to reduce sedentary time in this population group. the intervention has been developed through reviewing the literature on interventions to increase physical activity (a systematic review), an interview study to explore sedentary and physical activity behaviours within this population group, and through patient and public involvement.

Eligibility criteria:
inclusion criteria: * be aged ≥18 years, * self-report a clinical diagnosis of a long term physical health condition; * score 8 or more on the depression subscale of the hospital hospital anxiety and depression scales (zigmond \& snaith, 1983) suggesting the presence of depression; * speak english fluently; * live within greater manchester exclusion criteria: * are not registered with a gp practice, * in receipt of palliative care, * report a diagnosis of severe mental health problems such as schizophrenia or bipolar disorder, * have had a recent bereavement

Keywords: sedentary lifestyle
risk factors related to thirst after surgery

Conditions: Postoperative Complications

Summary: to investigate the risk factors related to xerostomia (dry mouth) after surgery

dry mouth of postoperative makes the patient feel thirst, and the pain of the lips is cracked. it will also make the sputum thick and sticky, making it difficult for the patient to cough by himself. especially the elderly may have sputum accumulation and pneumonia. the incidence of dry mouth was 88%, 6-8 hours after abdominal surgery. initiating the motivation of this study, it is hoped that through research to understand the relevant factors causing dry mouth after surgery.

Eligibility criteria:
inclusion criteria: 1. hospitalized patients 2. elective surgery patients 3. \>19 years old patients exclusion criteria: 1. cognitive impairment patients 2. icu patients
an effectiveness and safety study of concerta® (methylphenidate hydrochloride) in the treatment of adolescents with attention deficit hyperactivity disorder

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: the purpose of this study is to evaluate the safety and effectiveness of concerta® (methylphenidate hydrochloride, a central nervous system (cns) stimulant) versus placebo for the treatment of attention deficit hyperactivity disorder (adhd) in adolescents..

the objective of this study is to evaluate the safety and effectiveness of concerta® (methylphenidate hydrochloride) in the treatment of adolescents with attention deficit hyperactivity disorder (adhd). this is a multicenter, randomized, double-blind, placebo-controlled study with adolescents ages 13-18 diagnosed with adhd. the study consists of four phases. the screening phase establishes the diagnosis of adhd and provides a one-week washout period without any adhd medication. the open-label titration phase initiates the treatment of patients with one concerta® 18 mg daily. thereafter, the dose is increased approximately every 7 days in 18 mg increments (to a maximum of 72 mg daily), until an individualized dose is identified, based on the clinical judgment of the investigator. during the double-blind phase, subjects are randomized to receive either their individualized concerta® dose or a placebo, for a period of 2 weeks. subjects who successfully complete the double-blind phase are eligible to receive concerta® for an 8-week, open-label, follow-up phase. the primary efficacy measurement is the total score of the adhd rating scale, evaluated by the investigator at the end of the double-blind phase. safety assessments include monitoring adverse events, electrocardiograms (ecg), blood pressure, pulse, height and weight throughout the course of the study. the study hypothesis is that concerta® is more effective than placebo in the treatment of attention deficit hyperactivity disorder in adolescents, and is well tolerated. titration phase: concerta® 18 mg taken orally, once daily, and increased approximately every 7 days in 18 mg increments up to a maximum daily dose of 72 mg. double-blind phase: individualized dose of concerta® or placebo for 2 weeks. open-label phase: individualized dose of concerta® for 8 weeks.

Eligibility criteria:
inclusion criteria: * diagnosis of attention deficit hyperactivity disorder (adhd) as defined by the diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) * children's global assessment scale rating of 41-70 at baseline (screening phase) exclusion criteria: * subjects who are known to not respond to methylphenidate * have had adverse experiences from methylphenidate or hypersensitivity to concerta or its components * have marked anxiety, tension or agitation * have glaucoma, ongoing seizure disorder, psychotic disorder, tourette's disorder or family history of tourette's disorder

Keywords: attention deficit hyperactivity disorder adhd concerta
the effect of uric acid decrement on endothelial function in patients with chronic renal failure

Conditions: Hyperuricemia; Chronic Kidney Disease

Summary: in this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on endothelial dysfunction in patients with chronic kidney disease.

endothelial dysfunction (ed) is a key event in the development of atherosclerotic cardiovascular disease observed in patients with chronic kidney disease (ckd). experimental models have shown that hyperuricemia causes hypertension and renin angiotensin system activation. in this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on ed in patients with ckd.

Eligibility criteria:
inclusion criteria: * laboratory finding of hyperuricemia * patients between ages of 18 and 60 years * non-diabetic patients * creatinine clearance values between 20 and 60 ml/min/1.73 m2 exclusion criteria: * low (\< 20 ml/min/1.73 m2) creatinine clearance, * patients with diabetes mellitus, ischemic heart disease, acute coronary syndrome, congestive heart failure (chf) (new york heart association class ii or greater), valvular heart disease and a history of cerebral infarction or transient ischemic attack. * patients taking urate lowering medication (allopurinol and probenecid)

Keywords: allopurinol chronic kidney disease endothelial dysfunction hyperuricemia uric acid vascular endothelium xanthine oxidase inhibitor
the effect of changing the eating speed on energy intake

Conditions: Oral Intake Reduced

Summary: it was hypothesized that eating a meal slowly would lead to a lower meal energy intake and lesser feelings of hunger and desire to eat and higher levels of fullness after the meal compared to eating the same meal more quickly.


Eligibility criteria:
inclusion criteria: * men and women ages 19-65 years. exclusion criteria: * severe obesity (bmi ≥ 40 kg/m2), * dieting, * taking medications that affect appetite, * participating in \> 150 min/wk of vigorous physical activity, * smoking, * drinking heavily (men: \> 14 alcoholic drinks/wk; women: \> 7 alcoholic drinks/wk), * self-reported disordered eating, * depression, * type 1 or 2 diabetes, * adrenal disease, or * untreated thyroid disease.

Keywords: eating speed energy intake
a study to compare the effect of transipeg 2.95 g or forlax junior 4 g in children with constipation

Conditions: Constipation

Summary: the study design combines a long-term safety and a dose range determination objective. the first 8 weeks of the study were primarily intended for the dose range determination, while the later visits were used for the comparison of long-term safety between the groups.


Eligibility criteria:
inclusion criteria: * childhood functional constipation * 6 months to \<16 years of age * male or female * for females of childbearing potential (after menarche): negative pregnancy test * moderately severe to severe constipation, defined as stool frequency \<3 stools/week * informed consent signed by parent(s) or legal acceptable representative(s), after sufficient oral and written information before entering the study, to be documented by the investigators in the case report form exclusion criteria: * functional non-retentive fecal incontinence * known metabolic or endocrine disorders (s.a. hypothyroidism) * neurologic disorders (s.a. spina bifida or spinal cord anomaly) * hirschsprung's disease (congenital megacolon) * anal anomaly * gastrointestinal surgery * drug induced constipation * mental retardation * cerebral palsy * treatment with other laxatives * drugs influencing gastrointestinal function (e.g., cisapride, erythromicin, imodium) * prior bowel surgery, except appendectomy * earlier participation in this trial * concurrent participation in any other clinical trial * participation in any other clinical study 6 months prior to inclusion * any use of a macrogol within 2 months prior to inclusion

Keywords: macrogol
dietary advanced glycation end-products and insulin resistance in overweight and obese humans

Conditions: Type 2 Diabetes; Insulin Resistance; Obesity

Summary: we hypothesize that reduction in dietary advance glycation endproducts (age) intake will increase insulin sensitivity and normalise insulin secretion in overweight and obese individuals through reduction of chronic low grade inflammation. we propose to test this hypothesis by performing euglycemic hypeinsulinemic glucose clamp and intravenous glucose tolerance test before and after low age diet and normal australian diet in a cross-over design. this study will provide information relevant to the development and prevention of type 2 diabetes.


Eligibility criteria:
inclusion criteria: * weight stable overweight and obese (bmi ≥ 25kg/m2) non-diabetic individuals, aged 18-50 years and healthy according to medical history, blood biochemistry and physical examination. exclusion criteria: * participants will be excluded if they: * are aged \ 50 years; * currently smoke, have high alcohol use; or a positive urine drug screening test; * have a history of: diabetes, cardiovascular and hematological disease, respiratory, gastrointestinal, endocrine, renal or central nervous system disease, psychosis or psychiatric disorder, active cancer within last 5 years. * are actively seeking to lose weight, or if their weight has changed by more than 10 kilograms in the previous 12 months. * have been taking medication within one month prior to commencing the study; * have acute inflammation (by history, physical or laboratory examination) * are on hormonal contraceptives, or pregnant (by hcg urine pregnancy screening test) or lactating * have highly unusual dietary habits or follow vegan diets (because of the difficulty in complying with the assigned diet). * have current diabetes (determined by history and/or 75g glucose ogtt) * are unable to provide informed consent

Keywords: insulin resistance insulin secretion advanced glycation end-products
effect of curcumin addition to standard treatment on tumour-induced inflammation in endometrial carcinoma

Conditions: Endometrial Carcinoma

Summary: this therapy aims to determine whether curcumin can inhibit tumor induced inflammation in patients with endometrial carcinoma. in addition, curcumin could possibly induce a better functioning of chemotherapy and a decrease in toxicity from chemotherapy. various studies have demonstrated that curcumin can have an effect on tumor growth and the development of metastases.

various cancer types are associated with chronic inflammation. during the formation of cancer the immune system is being activated by the tumor in order to evoke an anti-tumor immune response. however, as the tumor develops, this gives rise to a chronic inflammation, causing the immune system to malfunction. this is being highlighted by the fact that different chronic inflammatory diseases are associated with an increased risk of cancer (f.i. chronic inflammatory bowel diseases and colon cancer, prostatitis and prostate cancer, hepatitis and liver cancer). endometrial cancer reveals different aspects of inflammation, including cytokine secretion and the infiltration of immune cells in this type of tumors. it is presumed that hormonal fluctuations and genetic changes contribute to the formation of a pro-inflammatory environment that stimulates tumor growth. cancer cells of endometrial tumors do not only produce immunomodulatory mediators, but also attract different sorts of cells of the immune system that stimulate tumor growth. it has already been demonstrated in mice models and in vitro experiments that curcumin shows strong anti-inflammatory effects that can slow down tumor growth and/or prevent formation of metastases. in addition, it has been noticed in these models that curcumin also has a positive effect on the functioning of various chemotherapeutic drugs, causing their effect to enhance or their toxicity to decrease. clinical studies investigating the anti-inflammatory effect of curcumin are rare, but these studies do reveal a suppression of the inflammation. the primary reason why clinical studies with curcumin are rare is because of the bad intake of curcumin in the human body. recently, there has been a lot of research carried out regarding the development of new formulations of curcumin that lead to a better intake in the human body. the best nutritional supplement containing curcumin that has been developed so far is meriva®, which is commercialized in belgium under the name "curcuphyt".

Eligibility criteria:
inclusion criteria: * endometrial carcinoma at time of recurrence * no life-threatening metastases exclusion criteria: * other active malignancy * documented autoimmune disease * currently ongoing immunosuppressive therapy * simultaneous treatment according to other clinical trials * documented immune deficiency
lidocaine combined with sufentanil for preventing catheter-related bladder discomfort

Conditions: Prostate Cancer

Summary: the goal of this clinical trial is to evaluate the incidence and severity of postoperative catheter-related bladder discomfort after robot-assisted radical prostatectomy. the main question it aims to answer is to evaluate incidence of crbd immediately after extubation in resuscitation. a total of 20ml of 2% lidocaine and 1μg/ml sufentanil or 20ml normal saline was injected into the bladder of the participants through the catheter. after drug injection, the catheter was clamped for 20 minutes, and then 100ml normal saline was injected into the bladder through the catheter to flush out. then, the incidence of crbd was compared between the two groups.


Eligibility criteria:
inclusion criteria: 1. aged 18-79 years, asa class i-ii 2. participants undergoing robot-assisted radical prostatectomy under general anesthesia 3. signed informed consent and volunteered to participate in the experiment exclusion criteria: 1. urethral stricture, difficulty in inserting catheter or urethral bleeding during catheterization 2. a preexisting bladder disease such as an overactive bladder, bladder outflow obstruction, and neurogenic bladder 3. cognitive impairment or communication disorders 4. severe heart, lung, liver, kidney and immune system diseases 5. confirmed or suspected allergy to this trial drug
microbiological spectrum of the intraperitoneal surface after elective right-sided colon cancer

Conditions: Peritoneal Contamination After Ileocolonic Anastomosis; Wound Infection; Intra-abdominal Abscess

Summary: despite performing colonic surgery with strict asepsia measures, minimizing the contact of the colon lumen with the peritoneum, some contamination is nearly impossible to avoid. in stapled anastomosis, the hole opened in the colon is minimum, just the necessary for introducing the parts of the mechanical devices. in handsewn anastomosis, the colonic lumen is more exposed to the peritoneum, despite the colonic occlusion with clamps meanwhile the suture is performed. hypothesis: after stapled anastomoses, the peritoneal contamination should be lower than after handsewn ones.


Eligibility criteria:
inclusion criteria: * diagnosis of right-sided colon cancer and plans to undergo an elective surgery with curative aims.

Keywords: right-sided colon cancer ileocolonic anastomosis stapled anastomosis handsewn anastomosis peritoneal contamination microbiological spectrum
effect of supine or prone position after caesarean birth

Conditions: Respiratory Distress; Transient Tachypnea of the Newborn; Delayed Transition of the Newborn; Persistent Pulmonary Hypertension

Summary: respiratory distress is a frequent clinical diagnosis of babies delivered by elective caesarean birth. there has been no study comparing the efficacy of immediately positioning a newly born infant prone vs. supine for the first 30 60 seconds of life after delivery by caesarean birth.

this study hypothesizes that when the infant is prone they will have postural drainage, better dorsal lung expansion, less vagal response from suctioning and less agitation secondary to the righting reflex. this study will compare 1033 term babies divided by randomization into two groups prone and supine. during the study, care givers will monitor and record incidence and severity of respiratory distress, use of fio2 or respiratory support, admissions to nicu.

Eligibility criteria:
inclusion criteria: \* any woman not in labor who are undergoing elective cesarean birth at term, 37 to 41 completed weeks gestation. exclusion criteria: * any woman with prior rupture of membranes * diabetes mellitus, gestational diabetes, * any woman receiving sedation * using medication such as demerol, magnesium sulfate or general anesthesia * any woman who has a known drug history * any known macrosomia * known congenital anomalies or meconium stained fluid * any woman with illnesses such as maternal fever, chorioamnionitis, severe neonatal distress * any woman with compromised infant at delivery * oligohydramnios * history of antenatal steroids.